Comparative efficacy of Sorafenib, and Lenvatinib in Hepatocellular Carcinoma: a meta-analysis

Abstract

Hepatocellular carcinoma (HCC) is an important healthcare problem with developing therapeutic options. This meta-analysis evaluates the effectiveness and safety of lenvatinib and sorafenib, focusing largely on overall survival, progression-free survival, and adverse events. Both drugs promote overall and progression-free survival; however, lenvatinib outperforms the other in the latter regard. There are differences in safety profiles; sorafenib has larger confidence intervals and more prominent effects. Publication bias is negligible. Due to demographic considerations, care should be used when applying these results to different groups of people. This analysis contributes to our understanding of the therapeutic options for HCC by providing insightful information that researchers and healthcare providers may use when deciding on an option of treatment.